Kornimate/medical-research-clean huggingface dataset:
assessment of an orthopedic surgery rotation on musculoskeletal competency in emergency medicine residency training

Conditions: Educational Problems; Orthopedic Disorder; Emergencies

Summary: patient commonly present with orthopedic injuries in the emergency department. musculoskeletal education has not historically been emphasized in american medical schools, and the effectiveness of an orthopedic surgery rotation has not been well studied in emergency medicine (em) training. competency in musculoskeletal education has been tested previously with a validated instrument, the basic competency exam (bce), to assess baseline knowledge in primary care and emergency physicians. residents from 2 different em residency training programs will be given the bce to determine baseline musculoskeletal knowledge prior to their orthopedic surgery rotations. a post-test bce will be given to the residents from both em training programs upon completion of their orthopedic surgery rotation and compared.


Eligibility criteria:
inclusion criteria: * emergency medicine residents at either san antonio military medical center or university hospital exclusion criteria: * not emergency medicine residents at the inclusion sites.

Keywords: emergency department education
pilot trial of cognitive and behavioral treatment of compulsive hoarding compared to wait list control

Conditions: Obsessive-Compulsive Disorder

Summary: this study developed and tested a specialized cognitive and behavioral treatment for the symptoms of hoarding disorder, including excessive acquiring, difficulty discarding items, and extensive clutter in the home.

compulsive hoarding is characterized by excessive acquisition of possessions, difficulty discarding possessions, and excessive clutter. this condition is resistant to standard pharmacological and psychotherapeutic interventions that have proven effective in treating other obsessive compulsive spectrum disorders. this study aimed to determine the effectiveness of a specialized cognitive behavioral therapy (cbt) designed for treating hoarding symptoms. this study consists of three phases. in phase 1, pilot data from previous studies were examined to develop an intervention suitable for use in a waitlist trial. in phase 2, pilot study information were used to develop and test a treatment manual for compulsive hoarding. during this phase, treatment was applied flexibly to allow for variations in treatment duration and choice of techniques. during phase 3, participants were randomly assigned to 26 weekly sessions of cbt or to a 12-week wait-list control, followed by active treatment for a fixed duration of 26 sessions. therapist adherence and competence were assessed through audiotaped therapy sessions.

Eligibility criteria:
inclusion criteria: * display at least moderately severe hoarding symptoms * must live within 45 minutes of boston, ma or hartford, ct exclusion criteria: * ten or more sessions of cognitive behavior therapy for hoarding * concurrent psychotherapy or medications * suicidal, psychotic, or other psychiatric symptoms requiring hospitalization * compulsive buying symptoms that are part of a manic phase of bipolar disorder * mental retardation, dementia, brain damage, or other cognitive dysfunction that would interfere with the study

Keywords: hoarding disorder
single arm, prospective, open-label, multi-center clinical investigation for the demax guide wire

Conditions: Peripheral Vascular Diseases; Coronary Artery Disease

Summary: the objectives of this study are to confirm the safety and performance of the guide wire when used in patients with peripheral vascular or coronary vascular disease for diagnostic or treatment procedures and will be the pivotal trial for this device. this study intends to evaluate the guide wire in its ability to successfully deploy an intended diagnostic or therapeutic catheter according to the ifu without any device related deficiencies, time to reach a specified position, and total number of insertion attempts to reach a primary performance endpoint.


Eligibility criteria:
inclusion criteria: 1. age is 18 years old or older 2. written consent to participate in the study 3. all subjects must be candidates to undergo percutaneous peripheral or coronary diagnostic or interventional procedures where use of a guide wire is indicated. 4. eligible for catheter-based diagnostic or treatment procedure. a representative list of diseases and catheter-based treatments includes: suspicion of obstructive coronary artery disease manifest as myocardial infarction, angina pectoris, angina-equivalent, ischemic dysrhythmia, or evidence of ischemia or viability on non-invasive cardiovascular testing suspicion of peripheral vascular obstructive disease undergoing elective or urgent diagnostic and/or percutaneous therapeutic procedures. 5. palpable pulse of the proximal and distal radial artery on one or both arms 6. subjects must be suitable for a transfemoral vascular access 7. subjects undergoing elective or urgent percutaneous treatment of symptomatic arterial occlusive disease and intermittent claudication or cli of the sfa and/or popliteal arteries. 8. subjects with suspected narrowed or blocked arteries in the heart. exclusion criteria: 1. inability to provide consent 2. pregnant or lactating women 3. subjects actively participating in another drug or device investigational study and have not yet completed the primary endpoint follow-up period. 4. subjects with bilateral hand or arm misalignment / paresis that makes a radial access impossible 5. subject has a known allergy to the guide wire materials 6. subjects with emergent procedures acute ischemia, aneurysmal disease, common femoral or profunda interventions, or hybrid procedures were excluded. 7. subjects with severe infections 8. subjects with severe heart failure 9. subjects with severe physical weakness
evaluation of efficacy of full-mouth disinfection in generalized aggressive periodontitis patients

Conditions: Aggressive Periodontitis

Summary: the purpose of this study is to determine whether full-mouth disinfection is effective in the initial periodontal treatment of generalized aggressive periodontitis on clinical parameters, gingival crevicular fluid interleukin-1β (il-1β) and interleukin-17 (il-17) and periodontal pathogen levels compared with conventional initial periodontal treatment and full-mouth initial periodontal treatment. the investigators' hypothesis is to test whether full-mouth disinfection in the initial periodontal treatment of generalized aggressive periodontitis enhance the clinical, biochemical and microbiological parameters in comparison to conventional initial periodontal treatment and full-mouth initial periodontal treatment.

the present study aimed to compare the efficacy of conventional initial periodontal treatment (c-ipt), full-mouth disinfection ipt (fmd-ipt) and full-mouth ipt (fm-ipt) and the levels of gingival crevicular fluid interleukin-1β (il-1β) and interleukin-17 (il-17), aggregatibacter actinomycetemcomitans, porphyromonas gingivalis, fusobacterium nucleatum, prevotella intermedia, parvimonas micra and campylobacter rectus in patients with generalized aggressive periodontitis (gagp) over 6-months period. forty-two gagp patients were randomly assigned into 3 groups. ipt was performed in a quadrant-wise manner at 1-week intervals in c-ipt, in 2 sessions within 24 hours in fm-ipt, and in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours in fmd-ipt. fmd-ipt group also used daily 0,2% chlorhexidine for 3 weeks. at baseline, 3 and 6 months clinical parameters consisting of plaque index, gingival index, probing depth, bleeding on probing and clinical attachment level were recorded, gingival crevicular fluid and microbiological samples were collected. gingival crevicular fluid levels of il-1β and il-17 were analyzed using elisa. the quantitative real-time polymerase chain reaction method was used for the quantitative detection of periodontal pathogens.

Eligibility criteria:
inclusion criteria: * no systemic diseases that could influence the outcome of the therapy * no smoking * no medications affecting periodontal tissues * no pregnancy or lactation * presence of at least 15 teeth exclusion criteria: * received antibiotic treatment in the previous 3 months * smokers * pregnancy and lactation * received periodontal treatment in the previous 6 months * presence of less than 15 teeth * presence of systemic diseases

Keywords: periodontal debridement gingival crevicular fluid aggressive periodontitis interleukin-1beta interleukin-17 bacteria
acthar for treatment-resistant or treatment-intolerant proteinuria

Conditions: Idiopathic Focal Segmental Glomerulosclerosis

Summary: focal segmental glomerulosclerosis (fsgs) is a condition that harms the kidney "filters" that remove waste from the blood. proteins are supposed to stay in the blood. damaged "filters" let protein get into the kidney. fsgs is a serious condition that can lead to kidney failure. the only treatment for kidney failure is dialysis or kidney transplant. proteinuria means too much protein came through the kidneys into the urine. if the doctor cannot figure out what is causing the problem, it is primary (idiopathic) fsgs. this kind of fsgs is very hard to treat. this study will test acthar in patients with this condition who have not responded to other treatments. it primarily investigates how well the therapy is tolerated by the patients and how well they respond to this treatment.


Eligibility criteria:
inclusion criteria potential participants must meet the following summary criteria for inclusion in the study: * is male or non-pregnant, non-lactating female * has primary fsgs, is nephrotic and did not achieve at least partial proteinuria response with prior therapy * has been treated with an angiotensin converting enzyme inhibitor or receptor blocker (or have documented intolerance), for at least 4 weeks before screening * has blood pressure no higher than 150/90 mmhg * meets all other inclusion criteria detailed in the protocol exclusion criteria potential participants will not be eligible for the the study if they meet the following summary criteria: * has hepatitis b or c, tuberculosis, or other contraindication listed on the united states (us) prescribing information for acthar * has type 1 or type 2 diabetes mellitus or any clinically significant infection * has received specific treatments at exclusionary time points per protocol * has been involved in a therapeutic drug/device trial (other than for fsgs) within 4 weeks before screening * meets any other exclusion criteria detailed in the protocol * has any other condition that might, per protocol or in the opinion of the investigator, compromise: 1. the safety and well-being of the participant or their offspring 2. the safety of study staff 3. analysis of results

Keywords: fsgs primary fsgs idiopathic fsgs
safety and efficacy of idose® tr with cataract surgery vs. cataract surgery alone

Conditions: Glaucoma, Open-angle; Ocular Hypertension (OHT); Phacoemulsification Cataract Surgery

Summary: this trial will evaluate the safety and iop -lowering efficacy of administering an idose tr (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

this is a phase 4 randomized, double-masked, parallel group trial designed to evaluate the safety and iop-lowering efficacy of administering idose tr (travoprost intracameral implant 75 mcg) in conjunction with uncomplicated cataract surgery (phacoemulsification with a posterior chamber intraocular lens) compared to uncomplicated cataract surgery alone, in patients with open-angle glaucoma (oag) or ocular hypertension (oht).

Eligibility criteria:
inclusion criteria: * cataract diagnosis: clinically significant age-related cataract eligible for phacoemulsification in the study eye. * oag or oht diagnosis: either oag (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or oht in the study eye (i.e., eye to undergo cataract surgery) exclusion criteria: * active corneal inflammation or edema. * retinal disorders not associated with glaucoma.
prevention of pneumococcal infections: impact collaborative medico-pharmaceutical care structured to improve vaccination coverage of patients at risk.

Conditions: Streptococcus Pneumoniae Infection

Summary: in france, streptococcus pneumoniae is the leading agent bacterial involved in community lung disease and meningitis. the frequency of these infections and their mortality increase significantly in those at risk such as patients with certain chronic diseases, immunocompromised or on immunosuppressive therapy. this population, despite regular monitoring, has a limited pneumococcal vaccine coverage of around 20%. by carrying out a reconciliation of treatments upon admission to hospital, the clinical pharmacist can detect those without up to date pneumococcal vaccination status. the goal of this management is to make the patient aware of the need for vaccination and organization upon return home. thus, this limited pneumococcal vaccination coverage would benefit from intervention by regional clinical pharmacy activities. the study investigators want to study the impact of a structured medico-pharmaceutical collaboration on pneumococcal vaccination of patients with risk on discharge from hospital. the investigators hypothesize that this collaboration in patients at risk of infection with pneumococcus could significantly increase their anti-pneumococcal vaccination coverage


Eligibility criteria:
inclusion criteria: * the patient must have given their free and informed oral consent * the patient must be a member or beneficiary of a health insurance plan * the patient is admitted to full hospitalization in a surgical or medical department. * the patient will benefit from a reconciliation of drug treatments. * the patient is considered at risk of pneumococcal infection according to the recommendations of march 2017 of the high council of public health (hcsp) * pneumococcal vaccination is not up to date according to the hcsp 2017 recommendations. exclusion criteria: * the subject is participating in a category 1 interventional study * the patient has participated in a category 1 trial within the previous 3 months or is in a period of exclusion determined by a previous study * it is impossible to give the subject informed information * the patient is under safeguard of justice or state guardianship * the patient is not in a fit state to express consent * the patient is pregnant, parturient or breast feeding
trial of amnioechange in gastroschisis affected foetuses

Conditions: Gastroschisis

Summary: hypothesis: gastroschisis is a localised disruption of the abdominal layer. it occurs early in gestation, and the bowel is therefore bathing in the amniotic fluid and can be constricted at the level of the abdominal hole. the bowel is therefore submitted to different injuries partly attributable to the contact with amniotic fluid contaminated by digestive compounds and inducing an inflammatory reaction. experimental studies on animal models and preliminary data in humans indicate that changing regularly the amniotic fluid (i.e. amnioechange) would improve the outcome of theses fetuses and then neonates.

primary objective: to compare prospectively the effect of amnioechange against classical care on the delay of full enteral feeding in gastroschisis affected foetuses study: * multicenter, randomized. * inclusion at 20 ga (gestational age) weeks. * amnioechange every 2 weeks from 30 ga weeks subject: 140 inclusion during 3 years analysis: triangular sequential evaluation

Eligibility criteria:
inclusion criteria: * seen before 30 ga weeks * normal karyotype * single pregnancy * isolated gastroschisis * no associated disease (maternal) * accept randomization and understand the study exclusion criteria: * maternal diabetes * maternal infection with hiv, hepatitis * preexistent oligohydramnios before inclusion
alpps combined with tislelizumab in liver malignancy

Conditions: Liver Malignant Tumors

Summary: study design: prospective, single-center, phase iia clinical trial; primary endpoint: recurrence free survival; secondary endpoints: safety, overall survival; main characteristics of patients: liver malignancy, required (extended) hemihepatectomy, insufficient liver reserve; study approaches: the experimental group is treated with alpps combined with tislelizumab, and the control group was treated with alpps; sample size: 20 (10:10); study process: in experimental group, patients who meet the inclusion criteria will receive alpps stage i surgery, treated with tislelizumab 2-4 weeks after stage i surgery, and receive alpps stage ii surgery 2-4 weeks after tislelizumab treatment, and treated with tislelizumab q3w 6-12 months after stage ii surgery; in control group, patients who meet the inclusion criteria will receive alpps stage i surgery, and receive alpps stage ii surgery 3-6 weeks after stage i surgery.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years and ≤70 years; 2. ecog physical condition score: 0\~1; 3. clinical/pathological diagnosis of primary liver cancer or intrahepatic metastatic colorectal cancer; 4. clinical evaluation requires (extended) hemihepatectomy; 5. liver function child a level 6. sflr \< 30% 7. the main organs function well, and the examination indicators meet the following requirements: routine blood tests: hemoglobin ≥90 g/l (no blood transfusion within 14 days); neutrophil count ≥1.5×10\^9/l; platelet count ≥80×10\^9/l; biochemical examination: total bilirubin ≤2×uln (upper normal value); alt or ast ≤ 2.5×uln; endogenous creatinine clearance ≥ 50 ml /min (cockcroft-gault formula); 8. sign the informed consent voluntarily; 9. good compliance, and family members willing to cooperate with follow-up. exclusion criteria: 1. presence of extrahepatic organ/distant lymph node metastasis; 2. hilar lymph node metastasis cannot be radically resected; 3. patients with intrahepatic metastatic colorectal cancer had received second-line or above systemic therapy; 4. other uncured malignant tumors; 5. pregnant or lactating women who are pregnant during the study period need to withdraw from the clinical trial; 6. concurrent use of any other antitumor therapy in patients with primary liver cancer; 7. patients with intrahepatic metastatic colorectal cancer have been treated with antitumor therapy in addition to primary surgery and standard first-line/second-line therapy; 8. patients with a known history of other systemic serious diseases before screening; 9. long-term unhealed wounds or incomplete healing fractures; 10. previous organ transplantation history; 11. having a history of abuse of psychotropic substances and being unable to quit or having mental disorders; 12. a history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 13. concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study.
prognostic impact of cardiac imaging during suspected immune checkpoint inhibitor myocarditis

Conditions: Myocarditis

Summary: it consists of evaluating the advantage of routine detection of phigfbp-1 to reduce the total duration of hospitalization for patients with a risk of preterm labor before 32 weeks of gestation without increasing the number of preterm labour.

patient with a risk of preterm labor (ultrasound cervical length \< 25 mm +/- described or recorded uterine contractions) before 32 weeks of gestation will be hospitalized to receive tocolytic drugs and antenatal corticosteroid therapy according to the investigators gold standard protocol. after 48 hours, the participants will be assessed by examination, external tocodynamometry and the measure of cervical length by ultrasound. stabilized patients will be included and randomized into 2 groups of 210 patients each. the first group "a" will benefit from the standard protocol (extended hospitalization of 2 or 4 days according to the clinical and ultrasound assessment); whereas the second group, "b", will have the benefit of the detection of phigfbp-1.if the result proves negative, patients could be discharged early at day 2. in the case of a positive result, patients will follow the standard procedure because of the low positive predictive value of the test. the main outcome is the total duration of hospitalization.

Eligibility criteria:
inclusion criteria: all patients affiliated to the french social security system will be eligible, after signing a consent form, and presenting the following criteria * introduction within the last 3 months of at least one of the following icis: nivolumab, pembrolizumab, cemiplimab, avelumab, atezolizumab, ipilimumab, tremelimumab, durvalumab. * suspicion of myocarditis defined by the presence of at least one of the following criteria adapted from the european society of cardiology guidelines: * symptomatic patients (chest pain, dyspnea, palpitations, syncope/lipothymia) within 7 days of ici administration * new ecg abnormality (st-segment elevation, st-segment undershift, arrhythmia, conductive disturbances, t-wave inversion) * elevation of troponin above the 99th percentile of the laboratory reference value or, if troponin is already elevated before treatment, an increase of more than 30% of the baseline value * recent lvef decline or recent lv contraction abnormality on a tte * patient has given no objection translated with www.deepl.com/translator (free version) exclusion criteria: * age \<18 years * major under guardianship or curatorship * pregnant or breastfeeding women * patient not covered by a social security plan * hemodynamic or rhythmic instability * estimation of glomerular filtration rate by the mdrd formula \<30ml/min/1.73m2 * implantable equipment that does not allow for cmri
phase i study of ts-1 with concurrent radiotherapy to treat pancreatic cancer

Conditions: Metastatic Pancreatic Cancer

Summary: the purpose of this study is to determine whether combination of ts-1 and concurrent and short-course radiotherapy is feasible in metastatic pancreatic cancer. the rationale of this study primarily bases on the good efficacy of gemcitabine plus ts-1 and the great potential of local control of concurrent chemoradiotherapy in pancreatic cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or adenosquamous carcinoma * no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or immunotherapy used for pancreatic cancer * presence of at least one measurable lesion, which must meet the criteria of being ≥ 20 mm in at least one dimension by conventional ct/mri or ≥ 10 mm by spiral ct scan * age between 20 and 79 years at registration * ecog ps of 0 or 1 * adequate major organ functions * ability to take the oral study medication (ts-1) * no clinically significant abnormal ecg findings within 28 days (4 weeks) prior to registration * voluntarily signed the written informed consent form exclusion criteria: * pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to registration * presence of diarrhea ≥ ctcae v.4.03 grade 2 * concomitant active infection or significant co-morbid medical conditions * moderate or severe ascites or pleural effusion that requires drainage * central nervous system metastasis * prior or concurrent malignancies within the last 3 years * concomitant treatment with flucytosine, phenytoin or warfarin * pregnant women or nursing mothers, or positive pregnancy test * severe mental disorder * judged ineligible by physician for participation in the study due to safety concern